233 related articles for article (PubMed ID: 30299433)
1. The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery.
Wong QHY; Anderson RA
Curr Opin Endocrinol Diabetes Obes; 2018 Dec; 25(6):391-398. PubMed ID: 30299433
[TBL] [Abstract][Full Text] [Related]
2. Low Anti-Müllerian Hormone in Pediatric Cancer Survivors in the Early Years after Gonadotoxic Therapy.
Elchuri SV; Patterson BC; Brown M; Bedient C; Record E; Wasilewski-Masker K; Mertens AC; Meacham LR
J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):393-9. PubMed ID: 26924632
[TBL] [Abstract][Full Text] [Related]
3. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
Anderson RA; Su HI
Front Endocrinol (Lausanne); 2020; 11():574263. PubMed ID: 33117288
[TBL] [Abstract][Full Text] [Related]
5. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
6. [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
Krawczuk-Rybak M; Leszczyńska E; Wysocka J; Zelazowska-Rutkowska B
Pediatr Endocrinol Diabetes Metab; 2008; 14(2):99-103. PubMed ID: 18721496
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
8. The physiology and clinical utility of anti-Mullerian hormone in women.
Dewailly D; Andersen CY; Balen A; Broekmans F; Dilaver N; Fanchin R; Griesinger G; Kelsey TW; La Marca A; Lambalk C; Mason H; Nelson SM; Visser JA; Wallace WH; Anderson RA
Hum Reprod Update; 2014; 20(3):370-85. PubMed ID: 24430863
[TBL] [Abstract][Full Text] [Related]
9. Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.
Lunsford AJ; Whelan K; McCormick K; McLaren JF
Fertil Steril; 2014 Jan; 101(1):227-31. PubMed ID: 24083876
[TBL] [Abstract][Full Text] [Related]
10. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
Brougham MF; Crofton PM; Johnson EJ; Evans N; Anderson RA; Wallace WH
J Clin Endocrinol Metab; 2012 Jun; 97(6):2059-67. PubMed ID: 22472563
[TBL] [Abstract][Full Text] [Related]
11. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Anderson RA; Remedios R; Kirkwood AA; Patrick P; Stevens L; Clifton-Hadley L; Roberts T; Hatton C; Kalakonda N; Milligan DW; McKay P; Rowntree C; Scott FM; Johnson PWM
Lancet Oncol; 2018 Oct; 19(10):1328-1337. PubMed ID: 30220622
[TBL] [Abstract][Full Text] [Related]
12. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
13. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.
Shandley LM; Fothergill A; Spencer JB; Mertens AC; Cottrell HN; Howards PP
Fertil Steril; 2018 Mar; 109(3):516-525.e1. PubMed ID: 29428311
[TBL] [Abstract][Full Text] [Related]
14. Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment.
Rodgers RJ; Abbott JA; Walters KA; Ledger WL
Front Endocrinol (Lausanne); 2021; 12():689532. PubMed ID: 34557157
[TBL] [Abstract][Full Text] [Related]
15. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
16. Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women.
Dunlop CE; Anderson RA
Maturitas; 2015 Mar; 80(3):245-50. PubMed ID: 25596814
[TBL] [Abstract][Full Text] [Related]
17. Ovarian effects of radiation and cytotoxic chemotherapy damage.
Cosgrove CM; Salani R
Best Pract Res Clin Obstet Gynaecol; 2019 Feb; 55():37-48. PubMed ID: 30166215
[TBL] [Abstract][Full Text] [Related]
18. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.
Dillon KE; Sammel MD; Prewitt M; Ginsberg JP; Walker D; Mersereau JE; Gosiengfiao Y; Gracia CR
Fertil Steril; 2013 Feb; 99(2):477-83. PubMed ID: 23084267
[TBL] [Abstract][Full Text] [Related]
20. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.
Visser JA; Schipper I; Laven JS; Themmen AP
Nat Rev Endocrinol; 2012 Jan; 8(6):331-41. PubMed ID: 22231848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]